NASDAQ:LIPO Lipella Pharmaceuticals (LIPO) Stock Price, News & Analysis → $21,000 in profits in six weeks? (From InvestorPlace) (Ad) Free LIPO Stock Alerts $0.74 +0.00 (+0.27%) (As of 12:48 PM ET) Add Compare Share Share Today's Range$0.70▼$0.7650-Day Range$0.67▼$1.0452-Week Range$0.64▼$2.71Volume18,312 shsAverage Volume47,565 shsMarket Capitalization$4.66 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Lipella Pharmaceuticals alerts: Email Address Lipella Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside168.5% Upside$2.00 Price TargetShort InterestHealthy1.49% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$23,700 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.51 out of 5 stars 3.5 Analyst's Opinion Consensus RatingLipella Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageLipella Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.49% of the float of Lipella Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLipella Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lipella Pharmaceuticals has recently increased by 4.58%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldLipella Pharmaceuticals does not currently pay a dividend.Dividend GrowthLipella Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LIPO. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows3 people have added Lipella Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lipella Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $23,700.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders39.58% of the stock of Lipella Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.31% of the stock of Lipella Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioLipella Pharmaceuticals has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Preserve GoldTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Christine Lagarde, President of the European Central Bank, shared "Now we have in Europe this threshold, above 1,000 euros you cannot pay cash… if you get caught you are fined or you are going to jail". Are you prepared?Click here to get your complimentary retirement guide! About Lipella Pharmaceuticals Stock (NASDAQ:LIPO)Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.Read More LIPO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LIPO Stock News HeadlinesApril 17, 2024 | finance.yahoo.comLipella Pharmaceuticals Expands its Advisory Board to Include Oncology ExpertiseApril 17, 2024 | globenewswire.comLipella Pharmaceuticals Expands its Advisory Board to Include Oncology ExpertiseMay 7, 2024 | Birch Gold (Ad)The Sneaky IRS Tax Law that's Sweeping the U.S.In the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.April 5, 2024 | globenewswire.comLipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024April 3, 2024 | markets.businessinsider.comLipella Pharmaceuticals Announces Type C Meeting For LP-10 - Quick FactsApril 3, 2024 | globenewswire.comLipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic CystitisMarch 7, 2024 | finance.yahoo.comPRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare DiseaseMarch 5, 2024 | markets.businessinsider.comLipella Pharma's IND Application For LP-410 Gets FDA's ApprovalMay 7, 2024 | Birch Gold (Ad)The Sneaky IRS Tax Law that's Sweeping the U.S.In the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.March 3, 2024 | morningstar.comLipella Pharmaceuticals Inc Ordinary Shares LIPOMarch 1, 2024 | finance.yahoo.comLipella Pharmaceuticals Full Year 2023 Earnings: US$0.77 loss per share (vs US$0.64 loss in FY 2022)February 20, 2024 | finance.yahoo.comLipella Pharmaceuticals to Present at PropThink Digital Investor ConferenceFebruary 20, 2024 | globenewswire.comLipella Pharmaceuticals to Present at PropThink Digital Investor ConferenceFebruary 9, 2024 | finance.yahoo.comLipella Pharmaceuticals Inc. (LIPO)December 20, 2023 | finanznachrichten.deLipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones AccomplishedDecember 20, 2023 | finance.yahoo.comLipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones AccomplishedDecember 9, 2023 | morningstar.comLipella Pharmaceuticals Inc Ordinary SharesNovember 10, 2023 | markets.businessinsider.comLipella Pharma: FDA Grants Orphan Designation For LP-310 To Treat Oral Graft-versus-Host DiseaseNovember 10, 2023 | finance.yahoo.comFDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host DiseaseOctober 25, 2023 | finance.yahoo.comLipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq RulesOctober 24, 2023 | finance.yahoo.comLipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq RulesOctober 23, 2023 | finance.yahoo.comLipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo ConferenceOctober 22, 2023 | msn.comLipella Pharmaceuticals stock more than doubles in 3 days as FDA approves IND for OLP treatmentOctober 20, 2023 | benzinga.comWhat's Going On With Lipella Pharmaceuticals Stock?October 20, 2023 | msn.comInvestors Remain Cautious Over Fed Moves, Setting Wall Street Up for Lower OpenOctober 20, 2023 | benzinga.comGold Rises Over 1%; Schlumberger Shares Fall After Q3 ResultsOctober 20, 2023 | marketwatch.comLipella Pharmaceuticals Shares Soar on FDA ApprovalSee More Headlines Receive LIPO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lipella Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/07/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LIPO CUSIPN/A CIK1347242 Weblipella.com Phone412-901-0315FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside+168.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,620,000.00 Net Margins-1,025.93% Pretax Margin-1,026.44% Return on Equity-150.13% Return on Assets-127.22% Debt Debt-to-Equity RatioN/A Current Ratio8.91 Quick Ratio8.91 Sales & Book Value Annual Sales$450,000.00 Price / Sales10.35 Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book1.38Miscellaneous Outstanding Shares6,250,000Free Float3,776,000Market Cap$4.66 million OptionableNot Optionable Beta0.77 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Jonathan Kaufman M.B.A. (Age 57)Ph.D., Co-Founder, Chairman, CEO, President, Secretary & Treasurer Comp: $204.13kDr. Michael B. Chancellor M.D. (Age 65)Co-Founder, Chief Medical Officer & Director Comp: $195.83kMr. Douglas Johnston CPA (Age 39)Chief Financial Officer Comp: $185kMs. Michele GruberDirector of OperationsKatie JohnstonControllerKey CompetitorsChina PharmaNYSE:CPHIPetros PharmaceuticalsNASDAQ:PTPINexImmuneNASDAQ:NEXIOragenicsNYSE:OGENExicureNASDAQ:XCURView All CompetitorsInsidersJonathan H KaufmanBought 30,000 shares on 3/18/2024Total: $23,700.00 ($0.79/share)View All Insider Transactions LIPO Stock Analysis - Frequently Asked Questions Should I buy or sell Lipella Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lipella Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" LIPO shares. View LIPO analyst ratings or view top-rated stocks. What is Lipella Pharmaceuticals' stock price target for 2024? 1 Wall Street research analysts have issued twelve-month target prices for Lipella Pharmaceuticals' shares. Their LIPO share price targets range from $2.00 to $2.00. On average, they expect the company's share price to reach $2.00 in the next twelve months. This suggests a possible upside of 168.5% from the stock's current price. View analysts price targets for LIPO or view top-rated stocks among Wall Street analysts. How have LIPO shares performed in 2024? Lipella Pharmaceuticals' stock was trading at $1.02 at the beginning of 2024. Since then, LIPO stock has decreased by 27.0% and is now trading at $0.7450. View the best growth stocks for 2024 here. Are investors shorting Lipella Pharmaceuticals? Lipella Pharmaceuticals saw a decrease in short interest in March. As of March 31st, there was short interest totaling 43,700 shares, a decrease of 17.7% from the March 15th total of 53,100 shares. Based on an average daily volume of 57,100 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.2% of the shares of the stock are sold short. View Lipella Pharmaceuticals' Short Interest. When is Lipella Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our LIPO earnings forecast. When did Lipella Pharmaceuticals IPO? Lipella Pharmaceuticals (LIPO) raised $7 million in an IPO on Tuesday, December 20th 2022. The company issued 1,217,391 shares at $5.75 per share. How do I buy shares of Lipella Pharmaceuticals? Shares of LIPO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LIPO) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersDave Ramsey Shocks Millions With US Dollar LunacyAmerican Hartford Gold GroupTrump is sounding the alarmPreserve GoldBiden’s Sneaky H.R. 5376 Is A Nightmare For Retirement SaversBirch GoldThe best inflation-proof investment DTIAI “wealth window” is closing June 25thParadigm PressWatch this FREE trading tutorial while it’s still availableInvestorPlaceCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipella Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
